Form 8-K - Current report:
SEC Accession No. 0001628280-25-016066
Filing Date
2025-04-02
Accepted
2025-04-02 08:29:59
Documents
21
Period of Report
2025-04-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K val-20250401.htm   iXBRL 8-K 43874
2 EX-4.1 exhibit41-8xk.htm EX-4.1 131792
3 EX-4.2 exhibit42-8xk.htm EX-4.2 137506
4 EX-4.3 exhibit43-8xk1.htm EX-4.3 134939
5 EX-10.1 exhibit101-8xk.htm EX-10.1 300950
6 EX-99.1 ex991_aprilofferingpressre.htm EX-99.1 13662
10 image_0a.jpg GRAPHIC 38508
11 val-20250401_g1.jpg GRAPHIC 16879
12 val-20250401_g2.jpg GRAPHIC 1656
  Complete submission text file 0001628280-25-016066.txt   1120707

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT val-20250401.xsd EX-101.SCH 1794
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT val-20250401_lab.xml EX-101.LAB 22590
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT val-20250401_pre.xml EX-101.PRE 13067
23 EXTRACTED XBRL INSTANCE DOCUMENT val-20250401_htm.xml XML 2820
Mailing Address 2223 AVENIDA DE LA PLAYA SUITE 208 LA JOLLA CA 92037
Business Address 2223 AVENIDA DE LA PLAYA SUITE 208 LA JOLLA CA 92037 (619) 400-1171
GRI Bio, Inc. (Filer) CIK: 0001824293 (see all company filings)

EIN.: 824369909 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40034 | Film No.: 25802273
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)